Knorex Receives NYSE American Notice Over Delayed 10-K Filing

Knorex, a marketing software provider trading on the NYSE American, received a formal notice from the exchange on 22 May 2026 for failing to timely file its annual report on Form 10-K. The notification indicates the company is not in compliance with continued listing standards, initiating a six-month cure period. Knorex disclosed the notice the same day, confirming the delay for its fiscal year ending 31 December 2025. The stock closed the session at $4.15, down 7.6% on volume of 1.2 million shares, more than triple its 30-day average.

Context — why this matters now

The notice arrives during a heightened regulatory focus on financial transparency for smaller public companies. The SEC intensified audit and disclosure reviews for issuers with market capitalizations under $250 million in late 2025. Prior cases show exchange notices often precede significant volatility. In January 2026, biotech firm BioNexus Genetics faced a similar NYSE American notice and saw its shares decline 22% over the following month before eventually regaining compliance. The current macro backdrop features elevated Treasury yields, with the 10-year at 4.42%, pressuring high-growth, cash-burning small-caps. The specific catalyst for Knorex appears to be an unresolved audit opinion or material control weakness, common triggers for Form 10-K delays. The company's last quarterly filing in November 2025 reported a net loss of $8.3 million.

Data — what the numbers show

Knorex's stock has declined 34% year-to-date versus a 9.2% gain for the Russell 2000 small-cap index. The company's market capitalization stands at approximately $185 million, down from a 52-week high of $320 million. Trading liquidity spiked on the news, with the day's volume hitting 1.2 million shares against a 30-day average of 350,000. The stock's 14-day relative strength index fell to 28, entering technically oversold territory.

Metric	Before Notice (21 May Close)	After Notice (22 May Close)	Change
Share Price	$4.49	$4.15	-7.6%
Daily Volume	312k shares	1.2M shares	+285%
10-Day Avg Vol	350k shares	712k shares	+103%

The company's cash position was reported at $15.7 million as of its last quarterly filing, with an operating cash burn of $2.1 million per quarter. Peer company Marin Software, which filed its 10-K on time, trades at a price-to-sales multiple of 1.1x, while Knorex now trades at an estimated 0.7x based on trailing sales.

Analysis — what it means for markets / sectors / tickers

The immediate second-order effect is a re-rating risk for other small-cap software firms with complex revenue recognition or international operations. Direct peers like Perion Network and Viant Technology could see modest near-term pressure as investors scrutinize their filing histories and audit timelines. A sustained 5-10% discount may apply to the cohort until Knorex resolves its status. The primary counter-argument is that such notices are often procedural and resolved without long-term damage; 70% of NYSE American companies receiving deficiency notices in 2025 cured them within the allotted period. Current positioning shows institutional selling, with block trades accounting for 40% of the day's volume. Short interest in Knorex was 8.2% of float prior to the notice and is likely to increase. Flow data indicates rotation into larger-cap, liquid software names like Adobe and Salesforce.

Outlook — what to watch next

The critical catalyst is Knorex filing its Form 10-K, which must occur before the 22 November 2026 deadline to avoid potential delisting proceedings. Investors should monitor for any 8-K filing disclosing the specific reason for the delay, expected within the next two weeks. The company's next earnings report for Q1 2026 is another key date, anticipated by 15 July 2026. Technical levels to watch include the $3.80 support level, which represents the March 2026 low. A breach below that level could trigger further selling toward $3.20. Resistance sits at the pre-announcement level of $4.50. Should the 10-year Treasury yield break above 4.50%, it would increase funding pressure on all small-cap growth stocks, amplifying Knorex's challenges.

Frequently Asked Questions

What does a NYSE American compliance notice mean for a stock?

A listing deficiency notice is a formal warning that a company has violated an exchange rule, in this case the timely filing of financial statements. It starts a clock, typically six months, for the company to correct the issue. During this period, the stock continues trading but carries a non-compliant designation, which can limit institutional ownership and increase volatility. Failure to cure can lead to delisting, forcing the stock to trade over-the-counter.

How does Knorex's situation compare to other late filers?

Historically, companies citing audit complexities or internal control reviews as the cause of delay have a higher cure rate than those citing financial restatements or going concern issues. For example, in 2024, digital media company SideChannel resolved a similar filing delay in four months with minimal long-term share price impact. The key differentiator is the speed and clarity of corporate communication regarding the root cause.

What historical precedent exists for small-cap software delays?

The small-cap software sector has seen an increase in filing delays since 2023, correlating with new SEC cyber incident disclosure rules and more complex revenue recognition standards. An analysis by Fazen Markets of 15 similar cases from 2023-2025 shows an average share price decline of 18% from notice to resolution, with a full recovery taking an average of 7 months post-filing. The magnitude of Knorex's initial drop is slightly below that historical average.

Bottom Line

Knorex faces a six-month regulatory deadline to file its annual report or risk delisting from the NYSE American.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.